Versa Vascular is a developer of an implant system designed to treat tricuspid regurgitation by supporting native valve function.
Versa Vascular has raised $27.3M in total funding. The most recent round was Series C. The last funding was announced in July 2025.
Versa Vascular's investors include Santa Cruz Ventures.
Versa Vascular is headquartered in Santa Cruz, United States.
Versa Vascular is a developer of an implant system designed to treat tricuspid regurgitation by supporting native valve function.
Versa Vascular is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Versa Vascular — Funding & Investors." VCBacked, July 30, 2025, https://www.vcbacked.co/company/versa-vascular. Accessed August 14, 2026.
VCBacked. (2025). Versa Vascular — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/versa-vascular
{{cite web |title=Versa Vascular — Funding & Investors |url=https://www.vcbacked.co/company/versa-vascular |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated